Decitabine and Cedazuridine (ASTX727)

A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Severe Renal Impairment and Cancer Patients With Normal Renal Function

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
18 patients (estimated)
Sponsors
Taiho Oncology, Inc.
Tags
Cytidine Deaminase Inhibitor (CDAi), DNMT1 Inhibitor, Hypomethylating Agents (HMA)
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
2135
NCT Identifier
NCT04953897

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.